305 related articles for article (PubMed ID: 17440059)
1. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
Puri N; Khramtsov A; Ahmed S; Nallasura V; Hetzel JT; Jagadeeswaran R; Karczmar G; Salgia R
Cancer Res; 2007 Apr; 67(8):3529-34. PubMed ID: 17440059
[TBL] [Abstract][Full Text] [Related]
2. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
Ma PC; Schaefer E; Christensen JG; Salgia R
Clin Cancer Res; 2005 Mar; 11(6):2312-9. PubMed ID: 15788682
[TBL] [Abstract][Full Text] [Related]
3. Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice.
Onn A; Isobe T; Itasaka S; Wu W; O'Reilly MS; Ki Hong W; Fidler IJ; Herbst RS
Clin Cancer Res; 2003 Nov; 9(15):5532-9. PubMed ID: 14654533
[TBL] [Abstract][Full Text] [Related]
4. Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma.
Chattopadhyay C; El-Naggar AK; Williams MD; Clayman GL
Head Neck; 2008 Aug; 30(8):991-1000. PubMed ID: 18327775
[TBL] [Abstract][Full Text] [Related]
5. The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression.
Litz J; Sakuntala Warshamana-Greene G; Sulanke G; Lipson KE; Krystal GW
Lung Cancer; 2004 Dec; 46(3):283-91. PubMed ID: 15541812
[TBL] [Abstract][Full Text] [Related]
6. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
Ma PC; Kijima T; Maulik G; Fox EA; Sattler M; Griffin JD; Johnson BE; Salgia R
Cancer Res; 2003 Oct; 63(19):6272-81. PubMed ID: 14559814
[TBL] [Abstract][Full Text] [Related]
7. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
Li X; Wang X; Ye H; Peng A; Chen L
Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M
Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856
[TBL] [Abstract][Full Text] [Related]
9. Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature.
Shnyder SD; Hasan J; Cooper PA; Pilarinou E; Jubb E; Jayson GC; Bibby MC
Anticancer Res; 2005; 25(3B):1889-94. PubMed ID: 16158922
[TBL] [Abstract][Full Text] [Related]
10. High expression of Met/hepatocyte growth factor receptor suppresses tumorigenicity in NCI-H1264 lung carcinoma cells.
To C; Seiden I; Liu N; Wigle D; Tsao MS
Exp Cell Res; 2002 Feb; 273(1):45-53. PubMed ID: 11795945
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
12. E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models.
Nakagawa T; Tohyama O; Yamaguchi A; Matsushima T; Takahashi K; Funasaka S; Shirotori S; Asada M; Obaishi H
Cancer Sci; 2010 Jan; 101(1):210-5. PubMed ID: 19832844
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants.
McDaid HM; Lopez-Barcons L; Grossman A; Lia M; Keller S; PĂ©rez-Soler R; Horwitz SB
Cancer Res; 2005 Apr; 65(7):2854-60. PubMed ID: 15805287
[TBL] [Abstract][Full Text] [Related]
14. Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo.
Mukhopadhyay T; Sasaki J; Ramesh R; Roth JA
Clin Cancer Res; 2002 Sep; 8(9):2963-9. PubMed ID: 12231542
[TBL] [Abstract][Full Text] [Related]
15. The retinoid X receptor-selective ligand, LGD1069, inhibits tumor-induced angiogenesis via suppression of VEGF in human non-small cell lung cancer.
Fu J; Ding Y; Huang D; Li H; Chen X
Cancer Lett; 2007 Apr; 248(1):153-63. PubMed ID: 17027148
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy.
Stabile LP; Lyker JS; Huang L; Siegfried JM
Gene Ther; 2004 Feb; 11(3):325-35. PubMed ID: 14737093
[TBL] [Abstract][Full Text] [Related]
17. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
Pan BS; Chan GK; Chenard M; Chi A; Davis LJ; Deshmukh SV; Gibbs JB; Gil S; Hang G; Hatch H; Jewell JP; Kariv I; Katz JD; Kunii K; Lu W; Lutterbach BA; Paweletz CP; Qu X; Reilly JF; Szewczak AA; Zeng Q; Kohl NE; Dinsmore CJ
Cancer Res; 2010 Feb; 70(4):1524-33. PubMed ID: 20145145
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of synthetic VEGF-receptor binding antagonist, VGA1155.
Ueda Y; Yamagishi T; Samata K; Hirayama N; Aozuka Y; Tanaka M; Nakaike S; Saiki I
Anticancer Res; 2005; 25(6B):3973-7. PubMed ID: 16309186
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides.
Weerasinghe P; Garcia GE; Zhu Q; Yuan P; Feng L; Mao L; Jing N
Int J Oncol; 2007 Jul; 31(1):129-36. PubMed ID: 17549413
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
Wolff NC; Randle DE; Egorin MJ; Minna JD; Ilaria RL
Clin Cancer Res; 2004 May; 10(10):3528-34. PubMed ID: 15161712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]